Priovant Therapeutics
Priovant Therapeutics Logo
About
Pipeline
Clinical Trials
News, Publications & Presentations
Careers
Contact
NEWS
10/15/2024
Biotech Formed by Pfizer, Roivant Eyes Treatment for Rare Diseases
9/23/2024
Priovant Therapeutics Announces Receipt of Fast Track Designation from FDA for Brepocitinib in Non-Anterior Non-Infectious Uveitis (NIU) & Start of Enrollment of Brepocitinib Phase 3 NIU Program
9/6/2024
Progress, Potential, and Possibilities Podcast: Novel Therapies for Severe Autoimmune Diseases
8/5/2024
Empowered Patient Podcast: Developing Oral Treatment for Rare Autoimmune Diseases
7/29/2024
Priovant Therapeutics Announces Completion of Enrollment in Global Phase 3 Study Evaluating Brepocitinib in Dermatomyositis (VALOR)
7/19/2024
Roivant Recently Sold One Spinout for Billions. Is Priovant Next?
6/28/2024
Priovant - Finding Options to Treat Autoimmune Diseases
4/2/2024
Priovant Therapeutics Announces Positive Phase 2 NEPTUNE Study Results for Brepocitinib in Non-Infectious Uveitis (NIU), Showing Strongest Efficacy Data in NIU Observed to Date
7/25/2022
Behind Pfizer’s New Quest to Target a 'Transformation' in Pharma
6/28/2022
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
6/28/2022
Roivant Unveils Latest Spinout as Pfizer Entrusts JAK1/TYK2 to Priovant
6/28/2022
Pfizer, Roivant Unveil Priovant with High Potential TYK2/JAK1 Inhibitor
PUBLICATIONS & PRESENTATIONS
12/3/2024
Introduction to Priovant
11/17/2024
Brepocitinib, a Selective TYK2/JAK1 Inhibitor Under Evaluation for the Treatment of Dermatomyositis, Reduces Inflammatory Cytokine Signaling and Interferon-induced Apoptosis in Primary Human Epidermal Keratinocytes
7/15/2024
Brepocitinib, A Potent and Selective TYK2/JAK1 Inhibitor: Scientific and Clinical Rationale for Dermatomyositis
11/13/2023
Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
11/12/2023
Patient Reported Physical Function, Mental Health, and Treatment Patterns in Dermatomyositis
11/11/2022
Brepocitinib for the Treatment of Dermatomyositis: Pharmacologic and Clinical Rationale
5/23/2022
Use of Janus Kinase Inhibitors in Dermatomyositis: A Systematic Literature Review